If Egalet Wins At FDA, Arymo ER Still Might Not In Opioid Market

Potential sales impact of even broadest possible label for oral, intranasal and intravenous abuse remains a question mark given that abuse-deterrent products remain only a small percentage of market.

Egalet Corp. is hoping Arymo ER (morphine sulfate extended-release) will garner the broadest abuse-deterrent labeling among long-acting morphine products following a positive FDA advisory committee review. However, the potential sales impact of such a label remains a question mark given the current market dynamics.

On Aug. 4, FDA's Anesthetic and Analgesic Drug Products and Drug Safety and Risk Management advisory committees voted 18-1 for...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip